IDO1 and cancer: In conclusion, ubiquitination/deubiquitination as one of the mechanisms regulating post-translation modifications of IDO1 holds promise as a therapeutic target for cancer and has potential for combination therapy with ICB, but further in vivo experiments are needed for its validation (Fig. 4B).